NCT00455039 2023-08-14
INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients
University of New Mexico
Phase 1/2 Withdrawn
Clinical Trials
12 trialsNCT01138384 2023-08-04
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT00952692 2021-12-20
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
Duke University
Phase 1/2 Completed
NCT01118975 2019-11-13
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT01783756 2019-11-12
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Jonsson Comprehensive Cancer Center
Phase 1/2 Completed
NCT01589861 2017-03-28
PIKHER2
Institut Paoli-Calmettes
Phase 1/2 Suspended
NCT01172223 2016-11-02
LAPADO
Sana-Klinikum Lichtenberg
Phase 1/2 Completed
NCT00450892 2016-07-07
Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT01495884 2015-10-26
The Myocet/Lapatinib Study. ICORG 10-03, V5
Cancer Trials Ireland
Phase 1/2 Terminated
NCT01658358 2013-02-27
ErbB2 Positive Metastatic Breast Cancer
China Medical University Hospital
Phase 1/2 Terminated
NCT01044485 2012-09-25
LapDoc
Centre Georges Francois Leclerc
Phase 1/2 Completed
NCT00316407 2011-02-18
Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
Swedish Medical Center
Phase 1/2 Completed